Skip to main content
Caplight Logo









Neowise Biotechnology

Neowise Biotechnology

Private
SuzhouHealthcare & Life Scienceshttps://www.neowisebio.com/

Last Round

Series B

Jan 26, 2026

Total Funding Raised

$72.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neowise Biotechnology is a biotechnology company that develops TCR-T cell therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Data as a Service

AI Layer

Application

Keywords

TCR-T cell therapyTCR-Tsolid tumor treatmentcell therapyTCR discovery platformAI drug discoveryimmunotherapyTCR librarybioinformaticsclinical-stage biotechbiotech licensingKRAS G12VPRAME

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neowise Biotechnology Comparables

Compare Neowise Biotechnology with similar companies based on industry and business-model similarity.

Neowise Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Anocca
86%
T-Knife
85%
Beijing CorreGene Biotechnology Co., Ltd.
85%

Neowise Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 26, 2026
Series A ExtensionMar 15, 2023
Series AOct 14, 2021
AngelOct 1, 2020

Neowise Biotechnology Investors

Notable investors and investment history

Neowise Biotechnology investors
InvestorRounds
Oriza HoldingsSeries B
TF CapitalSeries A
健壹资本Series A
Baidu VenturesAngel
Suzhou Angel Investment Guidance FundSeries B
Marathon Venture PartnersSeries A Extension
Delian CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 26, 2026

    $28M round led by Apricot Capital

  • Mar 15, 2023

    $29M round with participation from Marathon Venture Partners and Oriza Seed.

Neowise Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neowise Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neowise Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Year Founded2020
Last FundingJan 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?